Invitae Corporation (NVTA) News

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invitae Reports Third Quarter 2023 Financial Results

Invitae Reports Third Quarter 2023 Financial Results PR Newswire SAN FRANCISCO, Nov. 8, 2023 Reported revenue...

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research...

Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 PR Newswire SAN...

Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results

Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer PR Newswire SAN FRANCISCO, Oct. 19, 2023 SAN...

Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer

Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing...

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports...

Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization

Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization PR Newswire SAN FRANCISCO, Oct. 3...